CD14 and acute myeloid leukemia: AML cell surface markers CLEC7A (CD369) and CD14 positively correlated with the AUC of venetoclax (r=0.68 and 0.64, p<0.0001), in other words, patients with AML presenting high CD14/CLEC7A expression exhibited reduced sensitivity to venetoclax monotherapy, suggesting their potential in predicting venetoclax resistance (105).